PMC:7600245 / 23242-23432
Annnotations
LitCovid-PD-MONDO
{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T84","span":{"begin":43,"end":51},"obj":"Disease"}],"attributes":[{"id":"A84","pred":"mondo_id","subj":"T84","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"study in patients (n = 80) with non-severe COVID-19 showed that favipiravir (1600 mg orally twice daily on the first day, then 600 mg orally twice daily for thirteen days) with INF-α had sig"}
LitCovid-PD-CHEBI
{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T319","span":{"begin":64,"end":75},"obj":"Chemical"},{"id":"T320","span":{"begin":177,"end":180},"obj":"Chemical"}],"attributes":[{"id":"A319","pred":"chebi_id","subj":"T319","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A320","pred":"chebi_id","subj":"T320","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"}],"text":"study in patients (n = 80) with non-severe COVID-19 showed that favipiravir (1600 mg orally twice daily on the first day, then 600 mg orally twice daily for thirteen days) with INF-α had sig"}
LitCovid-PubTator
{"project":"LitCovid-PubTator","denotations":[{"id":"638","span":{"begin":177,"end":182},"obj":"Gene"},{"id":"642","span":{"begin":9,"end":17},"obj":"Species"},{"id":"651","span":{"begin":64,"end":75},"obj":"Chemical"},{"id":"661","span":{"begin":43,"end":51},"obj":"Disease"}],"attributes":[{"id":"A638","pred":"tao:has_database_id","subj":"638","obj":"Gene:3451"},{"id":"A642","pred":"tao:has_database_id","subj":"642","obj":"Tax:9606"},{"id":"A651","pred":"tao:has_database_id","subj":"651","obj":"MESH:C462182"},{"id":"A661","pred":"tao:has_database_id","subj":"661","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"study in patients (n = 80) with non-severe COVID-19 showed that favipiravir (1600 mg orally twice daily on the first day, then 600 mg orally twice daily for thirteen days) with INF-α had sig"}